Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Proposes Non-U.S. Clinical Trials Follow Good Clinical Practices

This article was originally published in The Gray Sheet

Executive Summary

The Feb. 25 proposed rule amends regulations on acceptance of data from medical device clinical trials done outside the U.S. to support any submission to FDA to comply with good clinical practice standards.

You may also be interested in...

Industry: Global GCPs, Final Rule Should Precede FDA Foreign Study Guidance

Medical device makers are concerned about a lack of globally harmonized standards for good clinical practices, which they say could cause problems for a guidance FDA has drafted on studies conducted outside the U.S.

Collecting Foreign Data? Come Talk To Us, FDA Says

FDA has been accepting data from patients outside of the U.S. to support device approvals for years, but the sponsor should check with the agency in advance to ensure the foreign data meets the needs of the U.S. regulatory system, according to a new draft guidance. The guidance details the factors that could stand in the way of FDA accepting foreign data and provides examples of what could be done about it.

FDA Guidance Allows Limited Foreign Data To Approve Devices With Postmarket Caveat

As FDA puts more emphasis on postmarket data collection in its PMA approval process, the agency has released a final guidance on balancing premarket and postmarket studies.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts